Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2023 11:22 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference

Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for Friday, August 11, 2023 at 8:00 a.m. ET AUSTIN,...
August 03, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
July 27, 2023 16:05 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
July 27, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
July 13, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
June 29, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting

ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial...
June 14, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
June 08, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
June 01, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Provides Company Update Today

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
May 30, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023

Plus Therapeutics’ partnership with Medidata resulted in a valid historical control arm for the Company’s Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium (186Re) obisbemeda in...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right